# Nuclide record iomab-b (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/iomab-b/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "iomab-b" ;
  schema:name "Iomab-B"@en ;
  schema:alternateName "Apamistamab-I131"@en, "131I-apamistamab"@en ;
  schema:description "Iomab-B is Actinium's radioactive antibody that clears the bone marrow before a transplant for older patients with active relapsed acute myeloid leukaemia; the phase 3 SIERRA trial met its primary endpoint but the FDA asked for another study."@en ;
  schema:url <https://nuclide.cc/drugs/iomab-b/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=Iomab-B> ;
  nuclide:status "phase-3" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:modality "Radioimmunotherapy conditioning agent (anti-CD45 antibody labelled with iodine-131)" ;
  nuclide:related <https://nuclide.cc/isotopes/i-131/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioimmunotherapy/>, <https://nuclide.cc/technologies/radioligand-therapy/> ;
  nuclide:companies <https://nuclide.cc/companies/actinium-pharmaceuticals/> ;
  nuclide:trials <https://nuclide.cc/trials/nct02665065/> .